The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 12:30 - 3:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 12:30 - 3:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 12:30 - 3:30 pm (CEST)
.If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Two-color flow cytometric analysis of CD45RA expression on human peripheral blood lymphocytes. Human whole blood was stained with BD Horizon™ BV510 Mouse Anti-Human CD45RA (Cat. No. 563031) and PE Mouse Anti-Human CD45RO (Cat. No. 555493/561889) antibodies. The erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The two-color flow cytometric dot plot shows the correlated expression of CD45RA versus CD45RO for gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Two-color flow cytometric analysis of CD45RA expression on human peripheral blood lymphocytes. Human whole blood was stained with BD Horizon™ BV510 Mouse Anti-Human CD45RA (Cat. No. 563031) and PE Mouse Anti-Human CD45RO (Cat. No. 555493/561889) antibodies. The erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The two-color flow cytometric dot plot shows the correlated expression of CD45RA versus CD45RO for gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Two-color flow cytometric analysis of CD45RA expression on human peripheral blood lymphocytes. Human whole blood was stained with BD Horizon™ BV510 Mouse Anti-Human CD45RA (Cat. No. 563031) and PE Mouse Anti-Human CD45RO (Cat. No. 555493/561889) antibodies. The erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The two-color flow cytometric dot plot shows the correlated expression of CD45RA versus CD45RO for gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The HI100 monoclonal antibody specifically binds to the 220 kDa isoform of the human leukocyte common antigen, CD45RA. CD45RA is expressed on approximately 40-50% of peripheral CD4+ T cells, 50% of peripheral CD8+ T cells and on a portion of B cells and monocytes. The CD45RA antigen is expressed by naïve and activated T cells. CD45RA-specific antibodies are useful for the study of the suppressor/inducer subpopulation of CD4+ lymphocytes.
The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon™ Brilliant Violet™ family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon™ BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon™ BV510 conjugates are useful for the detection of dim markers off the violet laser.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.